Back to top
more

Galmed Pharmaceuticals (GLMD)

(Delayed Data from NSDQ)

$0.37 USD

0.37
24,302

-0.02 (-5.26%)

Updated Apr 29, 2024 12:15 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GLMD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Galmed Pharmaceuticals Ltd. [GLMD]

Reports for Purchase

Showing records 141 - 160 ( 192 total )

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 141

11/15/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 142

11/15/2017

Company Report

Pages: 22

Give Credit Where Credit Is Due; Initiating with Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 75.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 143

11/10/2017

Company Report

Pages: 7

3Q Recap: Major Catalysts From Aramchol Data in 1H18: ARRIVE and ARREST; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 144

11/03/2017

Industry Report

Pages: 7

Healthcare - Weekly NASH Newsletter: MRI-PDFF Is The New Favorite Toy In NASH Playground

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 145

10/27/2017

Company Report

Pages: 9

Post-AASLD KOL Presentation Highlights Aramchol''s Unique MOA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 146

08/08/2017

Company Report

Pages: 7

2Q Recap: Aramchol to ARRIVE and ARREST in 1H18; Raising PT to $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 147

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 148

05/24/2017

Company Report

Pages: 4

We are dropping coverage of GLMD shares to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 149

05/24/2017

Daily Note

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 150

05/16/2017

Company Report

Pages: 6

1Q17 Recap: Pre-Clinical Data Demonstrates Aramchol''s Anti-fibrotic Activity; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 151

04/24/2017

Industry Report

Pages: 6

NASH Splash No. 3: Tidbits from EASL 2017

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 152

03/27/2017

Company Report

Pages: 7

4Q16 Recap: ARREST Data in 2Q18; Anti-Fibrotic Data at EASL; PT to $12 on Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 153

01/19/2017

Industry Report

Pages: 12

Healthcare Monthly: NASH Is the New Foie Gras

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 154

11/07/2016

Company Report

Pages: 8

3Q16 Quarterly Results

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 155

11/07/2016

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 156

11/07/2016

Company Report

Pages: 7

3Q16 Recap: ARREST Enrollment Accelerates; Completion Appears Likely by Year End; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 157

09/08/2016

Daily Note

Pages: 3

New CSO Highlights the Aim of Pursuing New Indications, Perhaps Beyond the Liver

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 158

08/04/2016

Company Report

Pages: 8

Meaningful Risk of Enrollment Delay for ARREST; Maintain Buy and Reduce PT to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 159

07/06/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 160

07/05/2016

Company Report

Pages: 13

The NASH Waiting Game: Resuming Coverage with a Buy and a $6 Price Target

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 50.00

Research Provided by a Third Party